Company intelligence / Profile preview

MD Pharm

Seongnam-si, Gyeonggi-do, South Korea

Ownership: Private
Employees: ~25
Development stage: Other

Overview

MDpharma is a South Korean biotechnology company specializing in the development of innovative therapeutics using its proprietary Bio-Sync drug delivery platform. The company focuses on metabolic diseases, particularly non-alcoholic steatohepatitis (NASH), and oncology. Its lead candidate, MDP-101, is a liver-targeted thyroid hormone receptor beta (THR-beta) agonist designed to treat NASH with reduced systemic side effects. MDpharma aims to improve the efficacy and safety profiles of existing drug classes through targeted delivery and optimized pharmacokinetics. The company's pipeline also includes early-stage programs for solid tumors and inflammatory conditions.

Therapeutic areas: OncologyDermatologyGastroenterologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on MD Pharm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MD Pharm.

Explore the full profile